You just read:

Intarcia Presents Compelling 48-week Results for ITCA 650 - Data Underlines the Promise to Become the First Injection-free GLP-1 Therapy at the 47th Annual EASD Meeting in Lisbon

News provided by

Intarcia Therapeutics, Inc.

Sep 14, 2011, 12:00 ET